Arrhythmias & electrophysiology
Brugada Syndrome Ablation for the Prevention of Ventricular Fibrillation Episodes (BRAVE)
Primary result · First occurrence of VF or deathResult — go to the resultHazard ratio 0.288Authors' conclusion
Epicardial substrate ablation significantly reduces VF recurrence in patients with symptomatic BrS with implantable cardioverter-defibrillators and seems safe, supporting its potential role as a first-line therapy to prevent recurrent VF in patients with symptomatic BrS.
Study context
- Population
- Patients with symptomatic Brugada syndrome (BrS) with an implantable cardioverter-defibrillatorrandomized, of 67 screened, 2 withdrawals, 15 declined randomization and remained in a registry · ablation 25 · control 25 · registry 15
- Participants
- 52 patients
- Comparison
- Ablation therapy vs control
- Ablationn = 25
- Controln = 25reference
- Primary endpoint
- First occurrence of VF or death
- Follow-up
- 3 years
Methodological detailsinterim analysis planned after 50 patients randomized
- Interim analysis planned after 50 patients randomized
Primary result
As reported in the abstract
Hazard ratio
0.288
P = 0.0184
Further findings
Trial conduct
- At the interim analysis, the Data Safety Monitoring Board recommended early trial termination
Ventricular fibrillation (VF)-free among all ablation recipients (including crossovers and registry participants)
- VF free after a single procedure
- 83%
- VF free after a repeat ablation
- 90%
Safety
Complications of ablation
- Hemopericardium without a long-term sequel
- 1
Original publication
Brugada Syndrome Ablation for the Prevention of Ventricular Fibrillation Episodes (BRAVE). Heart Rhythm. Published 26 April 2025. doi:10.
Summarised from the published abstract; every number is checked against it